Dynamic Technology Lab Private Ltd Invests $988,000 in AtriCure, Inc. (NASDAQ:ATRC)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 32,330 shares of the medical device company's stock, valued at approximately $988,000. Dynamic Technology Lab Private Ltd owned 0.07% of AtriCure as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. State Street Corp raised its stake in shares of AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after acquiring an additional 63,002 shares during the period. Geode Capital Management LLC raised its position in AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock worth $32,326,000 after purchasing an additional 32,676 shares during the period. Silver Oak Securities Incorporated bought a new stake in AtriCure in the fourth quarter worth about $220,000. Calamos Advisors LLC boosted its position in shares of AtriCure by 27.9% during the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock valued at $3,382,000 after buying an additional 24,147 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of AtriCure during the third quarter valued at approximately $614,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded down $0.17 during trading on Friday, hitting $31.47. The stock had a trading volume of 80,506 shares, compared to its average volume of 665,992. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The stock has a 50-day simple moving average of $36.18 and a two-hundred day simple moving average of $34.25. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -33.07 and a beta of 1.65.

Remove Ads

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 3.20% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ATRC. JPMorgan Chase & Co. dropped their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, March 27th. Piper Sandler raised their price objective on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Oppenheimer raised their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Finally, JMP Securities reiterated a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $49.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.